Cytokine Signatures in Psoriatic Arthritis Patients Indicate Different Phenotypic Traits Comparing Responders and Non-Responders of IL-17A and TNFα Inhibitors

Cytokine Signatures in Psoriatic Arthritis Patients Indicate Different Phenotypic Traits Comparing Responders and Non-Responders of IL-17A and TNFα Inhibitors

This study aimed to explore the dynamic interactions between 32 cytokines and biomarkers in Psoriatic Arthritis (PsA) patients to compare cytokine signatures of treatment responders and non-responders. Biomarkers were measured before and after four months of treatment in 39 PsA patients initiating e...

Full description

Bibliographic Details
Main Authors:	Marie Skougaard, Sisse Bolm Ditlev, Magnus Friis Søndergaard, Lars Erik Kristensen
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	International Journal of Molecular Sciences
Subjects:	psoriatic arthritis cytokines bDMARDs phenotypes principal component analysis
Online Access:	https://www.mdpi.com/1422-0067/24/7/6343

Similar Items

Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients
by: Marie Skougaard, et al.
Published: (2024-03-01)

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
by: Eleni Kampylafka, et al.
Published: (2018-07-01)

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01)

The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis
by: Athanasios Vassilopoulos, et al.
Published: (2022-10-01)

Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis
by: Szu-Hsuan Wang, et al.
Published: (2022-10-01)

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry
by: Jerusalem Calvo-Gutiérrez, et al.
Published: (2024-02-01)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
by: Laura Cometi, et al.
Published: (2020-05-01)

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort studyResearch in context
by: Maxime Beydon, et al.
Published: (2023-12-01)

Four emerging immune cellular blood phenotypes associated with disease duration and activity established in Psoriatic Arthritis
by: Marie Skougaard, et al.
Published: (2022-11-01)

Biological treatment and exercise as an alternative to typical rheumatoid arthritis therapy: pathophysiology and effects
by: Artur Aghadi, et al.
Published: (2023-02-01)

PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
by: Stefan Siebert, et al.
Published: (2022-12-01)

Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg
by: Dubravka Ukalovic, et al.
Published: (2024-02-01)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
by: Claudia Iannone, et al.
Published: (2023-02-01)

Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties
by: Ylva Borgas, et al.
Published: (2020-06-01)

Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients
by: Simone Parisi, et al.
Published: (2024-01-01)

Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
by: Alisson Pugliesi, et al.
Published: (2023-07-01)

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
by: Santiago Rodrigues Manica, et al.
Published: (2020-08-01)

Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes
by: Ippei Miyagawa, et al.
Published: (2022-07-01)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
by: Krzysztof Bonek, et al.
Published: (2021-02-01)

Novel Therapies in Takayasu Arteritis
by: Francesca Regola, et al.
Published: (2022-01-01)

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
by: Rieke Alten, et al.
Published: (2022-10-01)

IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis
by: Marco Krasselt, et al.
Published: (2022-06-01)

The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
by: Jie Chang, et al.
Published: (2024-01-01)

Tapering of biological treatment in autoinflammatory diseases: a scoping review
by: Tatjana Welzel, et al.
Published: (2022-08-01)

The Role of M1/M2 Macrophage Polarization in Rheumatoid Arthritis Synovitis
by: Maurizio Cutolo, et al.
Published: (2022-05-01)

The effect of polypharmacy on rheumatoid and psoriatic arthritis treatment: retrospective study
by: Mete Kara, et al.
Published: (2023-11-01)

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
by: Iain B. McInnes, et al.
Published: (2022-10-01)

VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs
by: David Schub, et al.
Published: (2018-11-01)

The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study
by: Jun Won Park, et al.
Published: (2022-02-01)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
by: Vibeke Strand, et al.
Published: (2018-12-01)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
by: Ennio Lubrano, et al.
Published: (2022-12-01)

Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis
by: Maria Sofia Ciliento, et al.
Published: (2023-03-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
by: Maria Chiara Gerardi, et al.
Published: (2022-08-01)

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial
by: Marianne A. Messelink, et al.
Published: (2022-06-01)

Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future
by: Navarini L, et al.
Published: (2020-11-01)

Neuropathic Pain in Patients with Psoriatic Arthritis: A Bystander or a Gamechanger?
by: Ozan Volkan Yurdakul, et al.
Published: (2023-09-01)

Influence of the timing of biological treatment initiation on Juvenile Idiopathic Arthritis long-term outcomes
by: Filipa Oliveira Ramos, et al.
Published: (2023-09-01)

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
by: Juan M. Reyes, et al.
Published: (2023-03-01)

Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis
by: Klervi Golhen, et al.
Published: (2022-06-01)